MARKET

INFI

INFI

Infinity Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.650
-0.110
-3.99%
Opening 15:34 03/05 EST
OPEN
2.780
PREV CLOSE
2.760
HIGH
2.780
LOW
2.330
VOLUME
2.76M
TURNOVER
--
52 WEEK HIGH
5.98
52 WEEK LOW
0.6000
MARKET CAP
222.98M
P/E (TTM)
-3.7224
1D
5D
1M
3M
1Y
5Y
DLA Piper advises Piper Sandler & Co. as sole book-running manager in connection with US$92 million common stock offering by Infinity Pharmaceuticals
, /PRNewswire/ -- DLA Piper represented & Co. as sole book-running manager in connection with the public offering of common stock of Infinity Pharmaceuticals, a clinical-stage biotechnology company.
PR Newswire - PRF · 2d ago
Infinity to Present at the H.C. Wainwright Global Life Sciences Conference
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company, today announced that management will present at the H.C. Wainwright Global Life Sciences Conference, which is being held Tuesday, March 9th - Wednesday, March 10th, 2021...
BusinessWire · 3d ago
Indolent Lymphoma Treatment Market 2021 by Growing Demands, Sales, Revenue, Gross Margin, Geographical Regions, and Forecast to 2027
The Express Wire · 4d ago
Asthma Therapeutics Market Share, Size 2021 Analysis and Forecast to 2025 By Recent Trends, Developments in Manufacturing Technology and Regional Growth Overview | Says Industry Research Biz
The Express Wire · 4d ago
5 Stocks to Buy Now Trading Under $10 With Ample Upside Potential
247WallSt.com · 6d ago
Penny Stocks To Buy With Analysts Targeting 76%-209% Upside
Feb 24, 2021 (Penny Stocks via COMTEX) -- Analysts Are Bullish On These 4 Penny Stocks We've discussed penny stocks and analyst ratings many times before....
Penny Stocks · 02/24 21:12
5 Hot Penny Stocks With Big News This Week, Are They A Buy Now?
Feb 24, 2021 (Penny Stocks via COMTEX) -- These Penny Stocks Are Jumping After Big News This Week Some of the biggest things traders look for when it comes...
Penny Stocks · 02/24 21:11
Making A List Of Penny Stocks To Buy This Week? Analysts Like These 5
Feb 24, 2021 (Penny Stocks via COMTEX) -- 5 Penny Stocks To Buy According To These 4 Analysts I know it's the weekend of the Big Game, and you may be...
Penny Stocks · 02/24 21:11
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of INFI. Analyze the recent business situations of Infinity Pharma through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average INFI stock price target is 7.60 with a high estimate of 12.00 and a low estimate of 2.000.
EPS
Institutional Holdings
Institutions: 80
Institutional Holdings: 33.10M
% Owned: 39.34%
Shares Outstanding: 84.14M
TypeInstitutionsShares
Increased
10
1.53M
New
19
903.51K
Decreased
12
515.05K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.20%
Pharmaceuticals & Medical Research
+1.28%
Key Executives
Chairman/Chief Executive Officer/Director
Adelene Perkins
President/Treasurer
Lawrence Bloch
Senior Vice President/Secretary
Seth Tasker
Lead Director/Independent Director
Norman Selby
Director
Samuel Agresta
Independent Director
David Beier
Independent Director
Anthony Evnin
Independent Director
Richard Gaynor
Independent Director
Michael Venuti
No Data
About INFI
Infinity Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, development and delivery of medicines to treat diseases. The Company develops small molecule drugs that target disease pathways for potential applications in oncology. Its product candidate is duvelisib, also known as IPI-145, is an oral, dual-inhibitor of the delta and gamma isoforms of phosphoinositide-3-kinase (PI3K), for the treatment of hematologic malignancies, or blood cancers. The Company is also developing IPI-549, which is an orally administered, clinical-stage, immuno-oncology product candidate that selectively inhibits the gamma isoform of PI3K. In addition to duvelisib, the Company focuses to generate new product candidates for potential investigation in oncology. The Company also focuses on developing DYNAMO, CONTEMPO, BRAVURA, FRESCO, DYNAMO+R, DUO, SYNCHRONY and Duvelisib + Venetoclax.

Webull offers kinds of Infinity Pharmaceuticals Inc. stock information, including NASDAQ:INFI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, INFI stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading INFI stock methods without spending real money on the virtual paper trading platform.